|
Title Metabolic Effects of Resistant Starch Type 2: A Systematic Literature Review and Meta-Analysis of Randomised Controlled Trials |
|
Type Poster Presentation |
|
Theme Probiotics and Prebiotics: Excellence in Science and Clinical Translation |
|
Topic Probiotic and Prebiotic Clinical Research, From Newborns to Elderly |
|
Main Author Nicole Kellow1 |
|
Presenting Author Nicole Kellow1 |
|
Co-Author Mathhew Snelson2 Jessica Jong1 Deanna Manolas1 Smonda Kok1 Audrey Louise1 Romi Stern1 |
|
Department / Institution / Country Department of Nutrition, Dietetics & Food / Monash University / Australia1 Department of Diabetes / Monash University / Australia2 |
|
Background and Rationale Published evidence exploring effects of dietary resistant starch on cardiometabolic health is inconsistent. |
|
Objectives: Indicates the purpose of the study This review aimed to investigate the effect of dietary resistant starch type 2 (RS2) supplementation on body weight, subjective satiety ratings, fasting plasma glucose, HbA1c, insulin resistance (HOMA-IR) and lipid levels in healthy individuals and those with overweight/obesity, the metabolic syndrome (MetS) or type 2 diabetes mellitus (T2DM). |
|
Methodology: Describe pertinent experimental procedures Five electronic databases were searched for Randomised Controlled Trials (RCTs) published in English between 1982 and 2017, investigating the effect of dietary RS supplementation on cardiometabolic health. Trials were eligible for inclusion if they reported RCTs involving humans where at least one group received ≥10 grams of RS2 per day for ≥1 week, and measured body weight, satiety, glucose and/or lipid metabolic outcomes. Eligible studies were assessed for methodological quality using the Cochrane Risk of Bias Tool and subjected to qualitative and quantitative synthesis using a random effects model meta-analyses. |
|
Results: Summarize the results of the research Twenty RCTs involving 569 participants were included. RS2 supplementation significantly reduced serum triacylglycerol (TAG) concentrations (Mean difference= -0.11; 95% CI -0.18, -0.04, p=0.002) in healthy individuals (n=227), but had no effect on body weight, appetite/satiety, fasting plasma glucose, HbA1c, HOMA-IR, total cholesterol, LDL-cholesterol or HDL-cholesterol in any patient sub-groups. No serious adverse effects of RS2 were reported. Most studies had a moderate-high risk of bias, were of short duration (1-12 weeks) and contained small sample sizes (10-60 participants). |
|
Conclusions: State the main conclusions While a small reduction in TAG was observed in healthy individuals, RS2 supplementation provided no metabolic benefits in overweight/obese people or those with MetS or T2DM. High quality, long-term trials are now required to determine the efficacy of RS supplementation as a dietary strategy in the management of metabolic disease. (PROSPERO Registration No. CRD42017077875). |